DUBLIN--(BUSINESS WIRE)--Sep 12, 2018--The "Global Diabetic Foot Ulcers Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The Global Diabetic Foot Ulcers Therapeutics Market to grow at a CAGR of 11.3% during the period 2018-2022.

This report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market. One trend affecting this market is the increasing wound healing therapeutics. Various organizations are developing new wound healing therapeutics and agents for diabetic foot ulcers. According to the report, one driver influencing this market is the strong drug development pipeline. There is a surge in the number of drug pipelines being developed for the treatment of diabetic foot ulcers. Further, the report states that one challenge affecting this market is the increased product discontinuation. One of the most major challenges being faced by the vendors of the global diabetic foot ulcers therapeutics market is the high rate of product discontinuation and low number of approved drugs for treatment of diabetic foot ulcers.Market trendsIncreasing wound healing therapeuticsGrowing number of strategic alliancesIncrease in R&D activities

Key vendors

ALLERGANAlimera SciencesBausch HealthF. Hoffmann-La RocheRegeneron Pharmaceuticals

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Market Sizing

Part 06: Five Forces Analysis

Part 07: Pipeline Landscape

Part 08: Market Segmentation By Product

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers And Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/n6kpdp/global_diabetic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180912005426/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH DIABETES

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/12/2018 04:15 AM/DISC: 09/12/2018 04:15 AM

http://www.businesswire.com/news/home/20180912005426/en